REG - EMV Capital PLC - PDS: 36-Month Overall Survival Rate announcement

EMV CapitalAnnouncement

02/10/2024 16:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241002:nRSB7105Ga&default-theme=true

RNS Number : 7105G  EMV Capital PLC  02 October 2024

For immediate release

 

EMV Capital plc

 

("EMVC" or the "Company")

 

PDS Biotech PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in
Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and
Chemoradiation

100% 36-month overall survival (OS) and progression-free survival (PFS) rates
in patients fully treated with Versamune(®) HPV combined with chemoradiation
(N=8)

88% (15/17) of patients had a complete metabolic response

IMMUNOCERV Phase 2 clinical trial results presented at ASTRO Annual Meeting
2024

 

EMV Capital plc (AIM: EMVC), the deeptech and life sciences VC investment
group, reports that its portfolio company, PDS Biotechnology Corporation
(Nasdaq: PDSB), in which it holds a 3% direct holding, has announced that
updated data from the IMMUNOCERV Phase 2 clinical trial evaluating
Versamune(®) HPV (formerly PDS0101) with chemoradiation to treat locally
advanced cervical cancer were presented at the American Society for Radiation
Oncology (ASTRO) Annual Meeting 2024 in an oral presentation by Adam Grippin,
M.D., Ph.D., of The University of Texas MD Anderson Cancer Center. The
abstract was granted Basic/Translational Science Award from the ASTRO Annual
Meeting Steering Committee.

 

PDS Biotech is a late-stage immunotherapy company focused on transforming how
the immune system targets and kills cancers and the development of infectious
disease vaccines

 

Ann Klopp, M.D., Ph.D., Professor of Radiation Oncology and Head of the
Gynecologic Section at MD Anderson said:

 

"HPV is responsible for virtually all cervical cancers and presents an
opportunity for immunologic targeting.(1)  However, there are currently no
FDA-approved HPV-targeted immunotherapies to treat cervical cancer.  These
data suggest that further investigation is warranted into the safety and
efficacy of Versamune(®) HPV in combination with standard of care in the
treatment of locally advanced cervical cancer."

 

The IMMUNOCERV Phase 2 clinical trial (NCT04580771) evaluated the efficacy,
safety and tolerability of Versamune(®) HPV in combination with
standard-of-care chemoradiotherapy for the treatment of locally advanced
cervical cancer. The investigator-initiated study enrolled 17 newly diagnosed
high-risk patients with large tumours of at least 5 cm in size. Highlights
from the presentation include:

 

·      All patients received at least 2 doses of Versamune(®) HPV.

·      Median follow-up was 19 months.

·      36-month overall survival (OS) rate was 84.4%, and 100% for the
eight patients who received all five doses of Versamune(®) HPV. Historical
published data show 36-month OS rate with chemoradiation in this population of
approximately 64%.(2)

·      36-month progression free survival (PFS) rate was 74.9%, among
all patients and 100% for the eight patients who received all five doses of
Versamune(®) HPV. Historical published data show 36-month PFS rate with
chemoradiation in this population of approximately 61%.(2)

·      Complete metabolic response (CMR) was achieved in 15/17 (88%)
patients.

·      Versamune(®) HPV appeared to be safe and well-tolerated. The
most common treatment-related toxicities were injection site reactions in
twelve patients (71%).

 

Frank Bedu-Addo, Ph.D., President and Chief Executive Officer of PDS Biotech
said:

 

"We are pleased that data from the Phase 2 IMMUNOCERV trial demonstrate
compelling clinical activity and a promising safety profile.  Based on our
continued research in various HPV-positive cancers, Versamune(®) HPV appears
to work in combination with a variety of therapeutic agents to generate
clinical responses and promote improved survival in patients with minimal
toxicity. We look forward to the next steps in the development of
Versamune(®) HPV for locally advanced cervical cancer."

 

1.    National Cancer Institute, Cervical Cancer Causes, Risk Factors and
Prevention. https://www.cancer.gov/types/cervical/causes-risk-prevention
(https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.cancer.gov%2Ftypes%2Fcervical%2Fcauses-risk-prevention&data=05%7C02%7Clangus%40rosewoodpr.co.uk%7C623de3a3eda94292d19108dce2eb70ff%7Cb9b2cf7e777c4d0caf8dae122314ff67%7C0%7C0%7C638634748086831665%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=Sp9Fqzf8hfpAubwiLxdbAoPcpXQPL9d44ypC6KVs3yU%3D&reserved=0)

2.    Rose PG, et al. Concurrent Cisplatin-Based Radiotherapy and
Chemotherapy for Locally Advanced Cervical Cancer. N Engl J Med.
1999;340:1144-53.

  A full version of PDS Biotech's announcement can be accessed here:

 

https://www.pdsbiotech.com/index.php/investors/news-center/press-releases/press-releases1/125-2023-news/889-iotechnologyeportsnducementrantnderasdaqis20231204
(https://www.pdsbiotech.com/index.php/investors/news-center/press-releases/press-releases1/125-2023-news/889-iotechnologyeportsnducementrantnderasdaqis20231204)

 

-Ends-

 

For more information, please contact:

 

 For more information, please contact:
 EMV Capital plc                                                             via Rosewood
 Ilian Iliev, CEO

 Panmure Liberum (UK) Limited (NOMAD and Broker)                             +44 (0)20 7886 2500
 Emma Earl / Will Goode / Freddy Crossley / Mark Rogers (Corporate Finance)
 Rupert Dearden (Corporate Broking)

 Rosewood (Financial PR)                                                     +44 (0)20 7653 8702
 John West / Llewellyn Angus / Lily Pearce

 

 

About EMV Capital plc (EMVC)

 

EMV Capital plc, formerly known as NetScientific plc, is a deep tech and life
sciences venture capital investment group with an international portfolio of
high-growth companies.

With a strategic focus on generating superior returns for investors from the
fast-growing sectors and technologies that will define our future; EMV Capital
invests in, manages and strengthens early stage IP-rich companies.

EMV Capital holds both direct equity stakes and carried interest in its
portfolio companies, creating an evergreen structure that supports extensive
growth and value creation. EMV Capital's investment thesis is realised through
these capital sources:

·    capital-efficient investments through Group balance sheet;

·    fund management of the Evergreen EIS and Martlet Capital Funds;

·    syndicated investments leveraging its network of third-party
investors.

EMV Capital's approach is characterised by its proactive management style,
aiming to advance portfolio companies to critical value inflection points by
actively engaging with them. Companies are supported through Board
representation and the use of its Value Creation Services practice.

Headquartered in London, with a Cambridge presence and strong international
links, EMV Capital is quoted on the AIM market of the London Stock Exchange.

www.emvcapital.com (http://www.emvcapital.com/)

About PDS Biotechnology

 

PDS Biotechnology is a late-stage immunotherapy company focused on
transforming how the immune system targets and kills cancers and the
development of infectious disease vaccines. The Company plans to initiate a
pivotal clinical trial in 2024 to advance its lead program in advanced
HPV16-positive head and neck squamous cell cancers. PDS Biotech's lead
investigational targeted immunotherapy Versamune(®) HPV is being developed in
combination with a standard-of-care immune checkpoint inhibitor, and also in a
triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate
(ADC), and a standard-of-care immune checkpoint inhibitor.

 

www.pdsbiotech.com (http://www.pdsbiotech.com)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  FURFSMFIEELSEDS